Abstract:
본 발명은 폐암의 조기 진단에 유용한 바이오마커로서 퀴에신-설프히드릴 옥시다제 1(Quescin-sulfhydryl oxidase 1), 피브릴린-1(Fibrillin-1), 라민-A/C(Isoform A of Lamin-A/C), 잠재 형질전환증식인자 베타-결합단백질 2(Latent-transforming growth factor beta-binding protein 2), 갈렉틴-1(Galectin-1), 딕오프관련단백질 3(highly similar to Dickkopf-related protein 3), 이질성 핵 리보핵단백질 A1(Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1), 14-3-3 엡실론 단백질(14-3-3 protein epsilon), 시스타틴-C(Cystatin-C), 결합 조직 성장인자 1(Isoform 1 of Connective tissue growth factor), 프로필린-1(Profilin-1), 세포외 간질단백질 1(Isoform 1 of Extracellular matrix protein 1), 히스톤 H2B 타입 2-E(Histone H2B type 2-E), 키네신 유사 단백질 KIF26A(Kinesin-like protein KIF26A), 징크 핑거 단백질 516(Zinc finger protein 516) 및 A-키나제 앵커 단백질 9(Isoform 1 of A-kinase anchor protein 9)로 이루어진 군에서 선택된 하나 이상의 단백질을 제공한다.
Abstract:
본 발명은 퀴에신-설프히드릴 옥시다제 1(Quescin-sulfhydryl oxidase 1 : QSOX 1)에 대한 항체, 이를 생산하는 하이브리도마 세포 및 이를 포함하는 폐암 진단용 조성물에 대한 것으로, 특히 퀴에신-설프히드릴 옥시다제 1(QSOX 1) 단백질에 특이적으로 결합하는 항체가 서열번호 2, 서열번호 6 또는 서열번호 9의 단백질 서열(항원결합부위(epitope))에 상응하는 결합부위를 가짐으로서 상기 퀴에신-설프히드릴 옥시다제 1(QSOX 1) 단백질과 높은 반응성을 가지기 때문에, 더욱 명확하게 폐암을 진단할 수 있는 효과가 있다.
Abstract:
PURPOSE: A composition for diagnosing lung cancer is provided to early diagnose lung cancer and to ensure sensitivity and specificity. CONSTITUTION: A composition for diagnosing lung cancer contains an antibody which specifically binds to one or more proteins selected from the group consisting of quescin-sulfhydryl oxidase 1, fibrillin-1, isoform A of lamin-A/C, latent-transforming growth factor beta-binding protein 2, galectin-1, Dickkopf-related protein 3, isoform A1-B of heterogeneous nuclear ribonucleoprotein A1, 14-3-3 protein epsilon, stanniocalcin-2, cystatin-C, isoform 1 of connective tissue growth factor, profilin-1, isoform 1 of extracellular matrix protein 1, histone H2B type 2-E, kinesin-like protein KIF26A, zinc finger protein 516, and isoform 1 of A-kinase anchor protein 9. The lung cancer is selected from the group consisting of adenocarcinoma of the lung, squamous cell carcinoma, large cell carcinoma, and small cell cancer. A kit for diagnosing lung cancer contains the composition as an active ingredient. A microarray for diagnosing lung cancer contains the composition as an active ingredient. [Reference numerals] (AA,GG) Patient number; (B1,H1) Gender; (B2,B3,B4,B5,H2,H3,H4) Male; (B6) Female; (CC,II) Age; (D1,J1) Histological classification; (D2,D4,D6,J2,J3,J4) Adenocarcinoma; (D3,D5) Squamous cell carcinoma; (E1,K1) Step; (E2,E5,K4) Step IIA; (E3,E4,E6,K3) Step IB; (F1,L1) Smoking history; (F2,F3) 30 boxes/year; (F4) 15 boxes/year; (F5) 70 boxes/year; (K2) Step IA; (L2) 80 boxes/year; (L3) 40 boxes/year; (MM,NN) Information X;